From the first use of chemotherapy in the 1960s to the first FDA-approved CAR T-cell therapy in 2017, the treatment of pediatric cancers has evolved to become safer and more effective, increasing survival rates from 10% to nearly 80%. Despite these pivotal successes, cancer remains a leading cause of death among children and adolescents. This webinar features talks focused on cell therapy for acute myeloid leukemia and updates on rare pediatric cancer.
Moderator: Timothy Cripe, MD, PhD, Nationwide Children's Hospital
Speakers + Topics:
-
Swati Naik, MBBS, St. Jude Children's Research Hospital
Updates on cell therapy for AML
-
Brian Ladle, MD, PhD
Advances in immune-based therapies for pediatric bone sarcomas
-
Jacquelyn Crane, MD, Children's Hospital of Philadelphia
Updates on rare pediatric cancer